Laboratory Corporation of America Holdings (NYSE:LH), also known as Labcorp, has undergone several financial updates. They announced their Q1 and Q2 2024 earnings call transcripts. Adjustments have been made to the FY2024 EPS estimates for the company and the Q2 earnings managed to surpass estimates. There were significant trades of the company's stock by Labcorp's EVP and Kerrii B. Anderson, Director of the company. Labcorp acquired select assets from Invitae and BioReference Health's diagnostics business. Also, the organization achieved FDA De Novo Marketing Authorisation for PGDx elio™ plasma focus Dx. Notable institutional activities include stake boosting by SG Americas Securities, Cetera Advisors, AMF Tjanstepension, and Tidal Investments, and share selling by several executives and Teachers Retirement system of Kentucky. Labcorp entered into a strategic relationship with Baystate Health for diagnostic laboratory services, expanded collaboration with Ultima Genomics, and launched a new test for preeclampsia in pregnant women.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 04 Oct 2023 07:00:00 GMT to Sun, 11 Aug 2024 14:59:14 GMT -
Rating -2
- Innovation 3
- Information 6
- Rumor -5
